Summary – At a time when drug regulators are intensifying enforcement against the sector across India, this article examines the regulatory framework within which drug regulators are required to act in the wake of the Bombay High Court’s recent order in Cadila Pharmaceuticals’ writ petition challenging the Maharashtra FDA’s directions restraining sale and distribution of its ACILOC products.